Results with PIQRAY

PIQRAY® (alpelisib) tablets + fulvestrant

What is PIQRAY used to treat?

PIK3CA mutations have been linked to cancer growth. But together, PIQRAY and fulvestrant is a treatment that can help slow the progression of HR+, HER2- metastatic breast cancer (mBC) with a PIK3CA mutation.

 

PIQRAY was studied in a clinical trial that included 572 postmenopausal women and men, with HR+, HER2- metastatic breast cancer (mBC) who had progressed on or after an aromatase inhibitor (a hormone therapy). Of the 341 people who tested positive for the PIK3CA mutation, 169 took PIQRAY + fulvestrant (hormone therapy), while 172 took fulvestrant alone.

How can PIQRAY help?

More time without disease progression.

People who tested positive for a PIK3CA mutation and took PIQRAY + fulvestrant lived progression-free for almost twice as long as those who took fulvestrant alone.

 

Median time people with PIK3CA mutation were progression-free from the start of treatment

Median time people with a PIK3CA mutation were progression free from the start of treatment

 

PIQRAY shrank tumors in more than twice as many people with a PIK3CA mutation in the clinical trial

Additional results of the trial showed that PIQRAY and fulvestrant worked together to shrink tumors in people with a PIK3CA mutation who had tumors large enough to measure. Of the 262 people with measurable disease, 126 took PIQRAY + fulvestrant and 136 took fulvestrant alone.

 

Twice as many people with a PIK3CA mutation who had tumors large enough to measure who took PIQRAY + fulvestrant had tumors that shrank or disappeared vs those who took fulvestrant alone.
*34.9% of people with a PIK3CA mutation who had tumors large enough to measure who took PIQRAY + fulvestrant saw their tumors shrink in size vs 14.7% of those who took fulvestrant without PIQRAY. And 0.8% of people with a PIK3CA mutation who had tumors large enough to measure who took PIQRAY + fulvestrant had their tumors completely disappear vs 1.5% of those who took fulvestrant without PIQRAY.